February 10, 2020
Nippon Shinyaku said on February 7 that the US FDA has accepted its oligonucleotide drug viltolarsen for priority review as a treatment of Duchenne muscular dystrophy (DMD), with a target action date set for the July-September quarter of 2020. The...read more